Old Web
English
Sign In
Acemap
>
authorDetail
>
Robert J Laliberte
Robert J Laliberte
Pfizer
Avelumab
Javelin
urothelial carcinoma
first line
Chemotherapy
3
Papers
3
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 subgroup analysis based on duration and cycles of 1L chemotherapy.
2021
Journal of Clinical Oncology
Yohann Loriot
Thomas Powles
Miguel Ángel Climent Duran
Srikala S. Sridhar
Joaquim Bellmunt
Daniel P. Petrylak
Jing Wang
Nuno Matos Costa
Robert J Laliberte
Alessandra di Pietro
Petros Grivas
Cora N. Sternberg
Show All
Source
Cite
Save
Citations (3)
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance.
2021
Journal of Clinical Oncology
Srikala S. Sridhar
Thomas Powles
Yohann Loriot
Miguel Ángel Climent Duran
Shilpa Gupta
Norihiko Tsuchiya
Aristotelis Bamias
Andrea Ardizzoni
Anders Ullén
Bo Huang
Nuno Costa
Robert J Laliberte
Alessandra di Pietro
Cora N. Sternberg
Petros Grivas
Show All
Source
Cite
Save
Citations (0)
Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.
2021
Journal of Clinical Oncology
Petros Grivas
Se Hoon Park
Eric Voog
Evgeny Kopyltsov
Howard Gurney
David Queiroz Borges Muniz
Frederic Rolland
Anne Birgitte Als
Begoña P. Valderrama
Jing Wang
Nuno Costa
Robert J Laliberte
Alessandra di Pietro
Thomas Powles
Joaquim Bellmunt
Show All
Source
Cite
Save
Citations (0)
1